Encouraging Data for Stroke Lytics in DOAC Users
(MedPage Today) -- Thrombolytic use in select stroke patients with recent direct oral anticoagulant (DOAC) ingestion did not raise the risk of the most feared bleeding complication, according to the largest-yet observational dataset.
In fact... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 3, 2023 Category: Cardiology Source Type: news
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
TUESDAY, Dec. 27, 2022 -- Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis (CAT), with the results sensitive to monthly drug costs, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2022 Category: Pharmaceuticals Source Type: news
The Latest on COVID-19, Immunity, and Thrombosis Risk The Latest on COVID-19, Immunity, and Thrombosis Risk
At ASH 2022, experts discuss how the virus breaches the immune system and how to recognize vaccine-related blood clots.MDedge News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - December 23, 2022 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
Thepositive CHMP opinion is based on the results of the HAVEN 6 study, which demonstrated effective bleed control and afavourable safety profile ofHemlibra in people with moderatehaemophilia A without inhibitors1Given that many people with moderatehaemophilia A may not receive prophylaxis, they may endure a worsened clinical burden with only 15% living a bleed-free life2If approved,Hemlibra, already approved for severehaemophilia A in the EU, will offer an effective and convenient prophylactic treatment option with afavourable safety profile for people with moderatehaemophilia ABasel, 16 December 2022 - Roche (SIX: RO, ROG...
Source: Roche Media News - December 16, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
Thepositive CHMP opinion is based on the results of the HAVEN 6 study, which demonstrated effective bleed control and afavourable safety profile ofHemlibra in people with moderatehaemophilia A without inhibitors1Given that many people with moderatehaemophilia A may not receive prophylaxis, they may endure a worsened clinical burden with only 15% living a bleed-free life2If approved,Hemlibra, already approved for severehaemophilia A in the EU, will offer an effective and convenient prophylactic treatment option with afavourable safety profile for people with moderatehaemophilia ABasel, 16 December 2022 - Roche (SIX: RO, ROG...
Source: Roche Investor Update - December 16, 2022 Category: Pharmaceuticals Source Type: news
Bad posture may cause 'blood vessels constriction' and deep vein thrombosis - warning
Many of the risk factors for deep vein thrombosis are avoidable. (Source: Daily Express - Health)
Source: Daily Express - Health - December 12, 2022 Category: Consumer Health News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
The assessment of venous thromboembolism risks associated with pregnancy and the postnatal period
This report finds that pregnant women and pregnant people could suffer a potentially fatal blood vessel blockage if their risk is not properly assessed during pregnancy and the first six weeks after birth. It aims to identify factors that limit the effectiveness of venous thromboembolism risk assessment policies and identify opportunities to improve patient safety. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 9, 2022 Category: Consumer Health News Source Type: news
Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
Risk for recurrent venous thromboembolism reduced for patients with isolated distal DVT receiving six additional weeks of rivaroxaban (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 30, 2022 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
WEDNESDAY, Nov. 30, 2022 -- For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2022 Category: Pharmaceuticals Source Type: news
Three 'common' sensations in 'upper limbs' that can signal blood clot - can ‘impact sleep'
Deep vein thrombosis normally strikes your legs, but it's worth being aware of how it can manifest in your upper body. (Source: Daily Express - Health)
Source: Daily Express - Health - November 24, 2022 Category: Consumer Health News Source Type: news
Is This Primary Exertional Headache?
Discussion
Commonly occurring primary headaches include tension, cluster and migraine headaches. “Other primary headaches” are often situational. Patients can have more than 1 type of these “other” headaches along with more common headaches. Other primary headaches as a group tend to be self-limited with long remission periods. Some other primary headaches include:
Thunderclap headache
Explosive sudden onset with maximum intensity in less 1 minute and resolution within 5 minutes usually
43/100,000 persons in adults
Primary or secondary
Secondary causes include intracranial hemorrhage, stroke, thro...
Source: PediatricEducation.org - November 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Two types of pain in your foot can signal a blood clot is forming, warns Thrombosis UK
You might also notice discolouration of the skin in the affected area. (Source: Daily Express - Health)
Source: Daily Express - Health - November 19, 2022 Category: Consumer Health News Source Type: news
Cochrane review of COVID-19 vaccines shows they are effective
A comprehensive review of all the evidence available from randomised controlled trials of COVID 19 vaccines up to November 2021 has concluded that most protect against infection and severe or critical illness caused by the virus.The review, a collaboration of independent, international experts, also found there was little or no difference between the number of people experiencing serious side effects after vaccination compared to those who were unvaccinated.The researchers, led by Isabelle Boutron, Professor of Epidemiology at Université Paris Cit é and Director of Cochrane France, analysed published data from 41 randomi...
Source: Cochrane News and Events - November 18, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Venous Thromboembolism After Total Shoulder Arthroplasty Venous Thromboembolism After Total Shoulder Arthroplasty
How often do total shoulder arthroplasty patients develop venous thromboembolism, and what are the risk factors?Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2022 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news
